The current price of INBX is $80.28 — it has decreased by 7.47% since the previous close. Data as of Nov 5, 2026.
INBX is up 11.44% over the past week, down 15.10% over the past month and down 2.42% over the past year. The price is below its 200-day moving average of $92.25.
Analysts' average 12-month price target for INBX is $285.00, which implies 255.01% upside from the current price. Individual estimates range from $245.00 to $325.00.
Of the 4 analysts covering Inhibrx Biosciences Inc., 3 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Inhibrx Biosciences Inc. has a market capitalization of $1.18B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Inhibrx Biosciences Inc. posted a loss of $2.34 per share against an estimate of -$2.28, missing expectations by 2.63%. Upcoming reports are listed in the earnings calendar.
Inhibrx Biosciences Inc. has not paid any dividends over the past year.
Companies most comparable to Inhibrx Biosciences Inc. include Celldex Therapeutics, Inc., Generate Biomedicines, Inc., Absci Corporation, Janux Therapeutics, Inc. and Immatics N.V.
In the latest trading session INBX moved between $79.22 and $86.75, a range of 9.38% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Inhibrx Biosciences Inc. shows a strong sell rating today. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Inhibrx Biosciences Inc. is buy. Technical ratings are indicators, not investment advice.
Over the past 52 weeks INBX has traded between $57.30 and $155.29. The current price is 48.30% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.